Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Melissa de los Reyes"'
Autor:
Sophie Wildsmith, Weimin Li, Song Wu, Ross Stewart, Nassim Morsli, Rajiv Raja, Qu Zhang, Jiabu Ye, Philip He, Jagdish Shetty, Alejandro Yovine, Nicholas Holoweckyj, Katia Real, Jill Walker, Magdalena Wrona, Melissa de los Reyes, Craig Barker, Jessica Whiteley, Robert Haddad, Lisa Licitra, Robert Ferris, Jérôme Fayette, Dan P. Zandberg, Lillian L. Siu, Ricard Mesía
Publikováno v:
Clinical Cancer Research. 29:2066-2074
Purpose: Biomarkers that predict response to immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) are needed. This retrospective study assessed tumor mutational burden (TMB) and outcomes in t
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Autor:
Lakshmi Nayak, Nathan Standifer, Jorg Dietrich, Jennifer L. Clarke, Gavin P. Dunn, Michael Lim, Timothy Cloughesy, Hui K. Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y. Wen, Mary Macri, Andrew J. Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de los Reyes, Nicholas M. Durham, Todd Creasy, Raymond Y. Huang, Thomas Kaley, David A. Reardon
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 12
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 12
Purpose: PD-L1 is upregulated in glioblastoma and supports immunosuppression. We evaluated PD-L1 blockade with durvalumab among glioblastoma cohorts and investigated potential biomarkers. Patients and Methods: MGMT unmethylated newly diagnosed patien
Autor:
Maria Libera Ascierto, Rajv Raja, Carl Barrett, Melissa de los Reyes, Song Wu, Micheal Oberst, Nathan Standifer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Emerging data suggest poor outcome to anti- PD(L)1 blocking agents in patients with STK11mut tumors1. In the current study, we undertook in-depth translational evaluations of three Ph1/Ph2 independent studies of Durvalumab ± Tremelimumab
Autor:
Jessica Whiteley, Rajiv Raja, Qu Zhang, Sophie Wildsmith, Han Si, Weimin Li, Helen Mann, Jérôme Fayette, Craig Barker, Magdalena Wrona, Dan P. Zandberg, Melissa de los Reyes, Ricard Mesia, Athena Matakidou, Zara Ghazoui, Lillian L. Siu, Nassim Morsli
Publikováno v:
Journal of Clinical Oncology. 38:6548-6548
6548 Background: Baseline tumor and germline biomarkers in R/M HNSCC were analyzed for predictive potential in pts benefitting from D or D+T. Methods: In HAWK (NCT02207530), 112 pts (PD-L1 tumor cells [TC]≥25%) received D (10 mg/kg Q2W for ≤12 m)
Autor:
Erika Farmer, Kamelia Zerrouki, Inna Vainshtein, Meina Liang, Jeffrey M. Riggs, Bhargavi Rajan, Chris Morehouse, Kevin Schifferli, Kimberly Rosenthal, Richard N. Hanna, Divya Sagar, Melissa de los Reyes, Roland Kolbeck, Miguel A. Sanjuan, Gary P. Sims, Jodi L. Karnell
Publikováno v:
Lupus Science & Medicine
Objective We investigated the mechanistic and pharmacological properties of anifrolumab, a fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal antibody in development for SLE. Methods IFNAR1 surface expressio
Autor:
Rajiv Raja, Michael Kuziora, Yong Ben, Ashok Kumar Gupta, Keith Steele, Chris Morehouse, Xiaoping Jin, Young S. Lee, Brandon W. Higgs, Koustubh Ranade, Melissa de los Reyes, Marlon Rebelatto, Carlos Bais, Fernanda Pilataxi, Joyce Antal, Li Shi
Publikováno v:
Journal of Clinical Oncology. 35:3037-3037
3037 Background: PD-L1 can be induced by IFNG in tumor cells (TC) and immune cells (IC). TC PD-L1 expression prevalence in UC is low and the relevance of scoring TC (in addition to IC) is not fully understood. We recently reported a positive correlat